Elastography Ultrasound in Localized Scleroderma (Morphea) Study
Launched by THE HOSPITAL FOR SICK CHILDREN · Feb 25, 2025
Trial Information
Current as of July 22, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Boys and girls 0-18 years of age at the time of disease onset with a new or existing diagnosis of localized scleroderma (LS) confirmed by a pediatric rheumatologist or dermatologist.
- • Presents with one active or inactive lesion, using the contralateral site for comparison at each visit, as long as the same lesion is evaluated at each time point. OR Presents with more than one lesion as far as both lesions are active or inactive.
- • Able to cooperate with clinical and US evaluation, and the parent or guardian is able to fill out interim patient history form.
- Exclusion Criteria:
- • Patients with other co-morbidities (e.g. systemic sclerosis, juvenile idiopathic arthritis, other systemic diseases).
- • Patients who present with one active and one inactive lesion.
- • Patients with lesions located in the face or head.
About The Hospital For Sick Children
The Hospital for Sick Children (SickKids) is a leading pediatric health care and research institution located in Toronto, Canada. With a commitment to advancing child health through innovative research, education, and clinical care, SickKids is recognized globally for its expertise in pediatric medicine. The hospital actively sponsors clinical trials aimed at improving treatment outcomes and enhancing the quality of life for children with various health conditions. By fostering collaboration among multidisciplinary teams and leveraging state-of-the-art facilities, SickKids strives to translate research findings into tangible advancements in pediatric care, ensuring that children receive the best possible treatments based on the latest scientific evidence.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Toronto, Ontario, Canada
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported